Perceptive Advisors LLC increased its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 102.4% during the first quarter, Holdings Channel reports. The firm owned 49,416 shares of the medical research company’s stock after buying an additional 25,000 shares during the period. Perceptive Advisors LLC’s holdings in Bio-Rad Laboratories were worth $9,851,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of BIO. Oppenheimer Asset Management Inc. bought a new position in shares of Bio-Rad Laboratories during the first quarter worth $428,000. Schwab Charles Investment Management Inc. increased its position in shares of Bio-Rad Laboratories by 8.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 113,148 shares of the medical research company’s stock worth $22,555,000 after buying an additional 9,164 shares during the period. Amalgamated Bank increased its position in shares of Bio-Rad Laboratories by 3.0% in the first quarter. Amalgamated Bank now owns 3,288 shares of the medical research company’s stock worth $655,000 after buying an additional 96 shares during the period. KCG Holdings Inc. bought a new position in shares of Bio-Rad Laboratories during the first quarter worth $450,000. Finally, BlackRock Inc. increased its position in shares of Bio-Rad Laboratories by 9,953.4% in the first quarter. BlackRock Inc. now owns 1,733,111 shares of the medical research company’s stock worth $345,478,000 after buying an additional 1,715,872 shares during the period. Institutional investors own 64.08% of the company’s stock.
Shares of Bio-Rad Laboratories, Inc. (BIO) traded up 0.11% during mid-day trading on Friday, reaching $220.61. 304,318 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $222.01 and its 200-day moving average price is $199.40. The company has a market capitalization of $6.53 billion, a PE ratio of 234.19 and a beta of 0.88. Bio-Rad Laboratories, Inc. has a one year low of $135.94 and a one year high of $230.40.
Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, May 4th. The medical research company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.27 by $0.14. Bio-Rad Laboratories had a net margin of 1.35% and a return on equity of 3.23%. The business had revenue of $500.05 million during the quarter, compared to analysts’ expectations of $477.76 million. During the same period in the previous year, the business posted $0.42 EPS. The business’s quarterly revenue was up 6.1% compared to the same quarter last year. On average, equities analysts expect that Bio-Rad Laboratories, Inc. will post $2.85 earnings per share for the current year.
WARNING: This article was reported by sleekmoney and is owned by of sleekmoney. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://sleekmoney.com/perceptive-advisors-llc-has-9-85-million-position-in-bio-rad-laboratories-inc-bio/1916186.html.
A number of analysts have commented on the stock. BidaskClub cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday. Zacks Investment Research raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and set a $244.00 target price for the company in a report on Monday, May 1st. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $250.00 target price on shares of Bio-Rad Laboratories in a report on Thursday, April 27th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $217.25.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/perceptive-advisors-llc-has-9-85-million-position-in-bio-rad-laboratories-inc-bio/1916186.html
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.